

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Regis Healthcare Ltd
ABN	11 125 203 054

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Linda Jane Mellors
Date of last notice	1 October 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Hazelwood Gates Pty Ltd (Davies and Mellors Family Trust) as nominated recipient by Linda Jane Mellors who is a Director of the trustee corporation and a beneficiary of the trust. Performance Rights granted to Dr Mellors by the Company pursuant to the FY25 LTI Plan approved at the Annual General Meeting held on 26 November 2024 (AGM) and subject to performance conditions measured over the 3-year performance period. The performance rights will have an exercise period of up to 7 years from the date of vesting. Each performance right generally entitles the holder to one fully paid ordinary share in the Company following vesting. The Board retains discretion to make a cash equivalent payment in lieu of an allocation of shares.
Date of change	30 December 2024
No. of securities held prior to change	284,270 Ordinary Shares 776,378 Rights (unquoted)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Rights (unquoted)
Number acquired	166,495 Performance Rights (unquoted)
Number disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	No cash consideration is payable. 166,495 Performance Rights issued under the FY25 LTI plan
No. of securities held after change	284,270 Ordinary Shares 942,873 Rights (unquoted)
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Performance Rights granted to Dr Mellors by the Company pursuant to the FY25 LTI plan approved at the AGM (subject to performance conditions measured over the 3-year performance period)

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.